FDX1 was highly expressed in IDH wildtype 1p/19 non-codeletion patients (Figures 7B, C), suggesting a differential FDX1 expression in glioma molecular subtypes and the value of survival and drug sensitivity prediction of FDX1. The gene discussed is FDX1; the disease is central nervous system cancer.